Jump to content

Stefan D. Anker

From Wikipedia, the free encyclopedia
Stefan D. Anker
Born
Berlin
NationalityGerman
Alma materHumboldt University Berlin, Imperial College London
Known forResearching heart failure
Scientific career
FieldsCardiology, heart failure, muscle wasting, cachexia, sarcopenia, treatment development, drugs & devices, clinical trials
InstitutionsUniversity Medical Center, Göttingen

Stefan D. Anker is a German cariologist who is Head of Field “Tissue Homeostasis and Cachexia" at Charité University, Berlin, Germany.[1] Previously, he was Professor of Innovative Clinical Trials at University Medical Center Göttingen in Germany.[2] The main focus of the Innovative Clinical Trials department was research in the field of chronic heart failure, including the development and clinical testing of new therapies.[3]

Education

[edit]

Anker studied medicine at Charité Medical School of Humboldt-University Berlin, Germany (1987-1993)[1] and completed his PhD at the National Heart and Lung Institute of Imperial College London, United Kingdom, in 1998.[citation needed]

Career and research

[edit]

Anker has had teaching appointments in the UK, Germany, Australia and Italy.[4]

His particular research interests include the pathophysiology and treatment of acute and chronic heart failure (CHF), cardiac device therapy, clinical evaluation of cardiovascular biomarkers, pathophysiology of muscle wasting, cachexia therapy[5] in CHF, ageing, sarcopenia and cancer.[6]

Anker serves on the editorial boards of European Heart Journal[7] and European Journal of Heart Failure.[8] He is founding Editor-in-Chief of the Journal of Cachexia, Sarcopenia and Muscle[9] and of ESC Heart Failure, which is the first open access heart failure journal.[10]

Anker has won two American Heart Association Young Investigator Awards[11][12] and has obtained two National Institutes of Health (NIH) grants (Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial),[13] two grants from the EU's Seventh Framework Programme for Research (FP7), and one Innovative Medicines Initiative / Horizon 2020 grant.[14]

Memberships

[edit]

Anker has been a member of the German Cardiac Society and of the European Society of Cardiology (ESC) since 1995. He is currently[when?] vice president of the ESC in charge of 'National Cardiac Societies and Communications.'[citation needed] He has been serving on the board of the ESC since 2012.[15] In addition, he has been serving on the board of the Heart Failure Association (HFA) of the ESC since 2006. He was HFA President between 2012 and 2014 and he chairs the HFA committee on regulatory affairs.[16]

Anker is the founding president of the International Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD).[17][18]

Selected publications

[edit]

Anker has authored more than 700 original papers, reviews, and editorials. Total citations exceed 46,000, including over 50 papers with more than 200 citations. He has an h-index of 104.[19][20]

Consensus meetings and guidelines

[edit]

Anker has participated in and chaired several consensus meeting and guidelines committees:

  • Chair, ESPEN Guidelines on Parenteral Nutrition: on cardiology and pneumology. (Anker et al., Clin Nutr 2009)
  • Co-chair, Consensus Group “The definition of Cachexia” (Evans et al., Clinical Nutrition 2008)[21]
  • AHA Consensus Group “State of the science: promoting self-care in persons with heart failure: a scientific statement from the American Heart Association.” (Riegel et al., Circulation 2009)[22]
  • ADQI 7 Consensus Group “Cardio-Renal Syndromes” (Ronco et al., Eur Heart J 2010)[23]
  • Co-chair, Consensus Group “Endpoints for Cachexia Trials & Nutrition for Cachexia and Sarcopenia” (Morley et al., JAMDA 2010)[24]
  • Nutritional recommendations for the management of sarcopenia. Co-chair. (Morley el al., JAMDA 2010)[25]
  • “Definition and classification of cancer cachexia” (Fearon et al. Lancet Oncol 2011)[26]
  • ESC/HFA Guideline on Diagnosis & treatment of acute and chronic heart failure (McMurray et al., EHJ 2012)[27]
  • HFA/WGTE of ESC Consensus on thromboembolism & anti-thrombotic therapy in heart failure with sinus rhythm (Lip et al. Eur J HF 2012)[28]
  • ESH/ESC Guidelines for the management of arterial hypertension. Reviewer. (Mancia et al. EHJ 2013)[29]
  • ESC/EASD Guidelines on diabetes, pre-diabetes, and cardiovascular diseases. (Ryden et al. EHJ 2013)[30]
  • SC/ESA 2014 Guidelines on non-cardiac surgery: cardiovascular assessment and management. (Kristensen et al. EHJ 2014)[31]
  • Reporting on patient reported outcomes in cardiovascular trials – Position statement of the ESC cardiovascular round table. (Anker et al. EHJ 2014)[32]
  • ESC/HFA Guideline on Diagnosis & treatment of acute and chronic heart failure (Ponikowski et al., EHJ 2016)[33]
  • Co-chair, Consensus Group “International Cachexia Definition – Update 2016” (ongoing)

Research

[edit]

Anker has been a member of more than 30 international clinical trial steering committees, chairing or co-chairing more than 10 (including the FAIR-HF,[34] TIM-HF,[35] BACH,[36] AUGMENT-HF,[37] ACT-ONE,[38] RESHAPE-HF2,[39] IMPULSE-HF,[40] FAIR-HF2,[41][42] Fair-HFpEF,[42] EMPORER-HFpEF trials[43]). He served in several data and safety monitoring boards (chairing five) and end-point committees (chairing three).[14] In 2015 and again in 2016, he was named in the Thomson Reuters Highly Cited Researchers list.[44]

Honors and awards

[edit]
  • 1998: "Ehrenmedaille der Charité Berlin" (honorary medal of Charité Medical School, Berlin)[citation needed]
  • 2000: Samuel A. Levine Young Investigator Award (Clinical Cardiology) for the AHA for the paper: Sharma R, Coats AJS, Anker SD. Cellular endotoxin desensitization in patients with severe chronic heart failure.[citation needed]
  • 2006: Samuel A. Levine Young Investigator Award (Clinical Cardiology) for the AHA for the paper: Okonko D, Poole-Wilson PA, Anker SD, Ponikowski P. Intravenous iron therapy in patients with chronic heart failure with and without anemia[45]
  • 2007: Young Investigator Award of the European HF Association for the paper: Okonko D, Anker SD, Poole-Wilson PA. Epo and inflammatory cytokines in patients with chronic heart failure – mechanistic studies.[citation needed]
  • 2011: Storz German Telemedicine Award 2011 for TIM-HF (together with Köhler)[citation needed]

2018: Copernicus Award from the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) and the Fundacja na rzecz Nauki Polskiej (FNP, Foundation for Polish Science)[46] for services to German-Polish research collaboration[47]

References

[edit]
  1. ^ a b "BCRT / Single News / Berlin-Brandenburger Centrum für Regenerative Therapien". www.b-crt.de (in German). Retrieved 2017-10-04.
  2. ^ "Universitätsmedizin Göttingen - Scientific staff". www.herzzentrum-goettingen.de. Retrieved 2017-05-17.
  3. ^ "Universitätsmedizin Göttingen - Innovative Clinical Trials". www.herzzentrum-goettingen.de. Retrieved 2017-05-17.
  4. ^ "ICI Meeting 2016 | Staff Members | Stefan D. Anker | Innovations". Retrieved 2017-05-17.
  5. ^ "This Potentially Fatal Syndrome Makes Your Body Literally Waste Away—And It's More Common Than You Know". Prevention. 2017-09-27. Retrieved 2017-10-04.
  6. ^ "Journal of Cachexia, Sarcopenia and Muscle". Wiley Online Library.
  7. ^ "European Heart Journal". academic.oup.com. Retrieved 2024-06-21.
  8. ^ "European Journal of Heart Failure". doi:10.1002/(ISSN)1879-0844. S2CID 115560449.
  9. ^ "Home". www.jcsm.info. Retrieved 2017-05-17.
  10. ^ "ESC Heart Failure". ESC Heart Failure. doi:10.1002/(issn)2055-5822.
  11. ^ AHA Samuel A Levine Young Investigator Award (Clinical Cardiology) 1st Prize for the paper: Sharma R, Coats AJS, Anker SD. Cellular endotoxin desensitization in patients with severe chronic heart failure, November 2000.
  12. ^ AHA Samuel A Levine Young Investigator Award (Clinical Cardiology) 1st Prize; for the paper: Okonko D, Poole-Wilson PA, Anker SD, Ponikowski P. Intravenous iron therapy in patients with chronic heart failure with and without anemia, November 2006.
  13. ^ Homma, Shunichi (2014-08-29). Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial (Report). clinicaltrials.gov.
  14. ^ a b "HFA Career Cafe 2017". www.escardio.org. Retrieved 2017-05-17.
  15. ^ "ESC Board". www.escardio.org. Retrieved 2017-05-17.
  16. ^ "Committees and Study Groups of the Heart Failure Association of the ESC". www.escardio.org. Retrieved 2017-05-17.
  17. ^ "Details of the SCWD board members". Sarcopenia, Cachexia and Wasting Disorders. Retrieved 2017-05-17.
  18. ^ "SCWD - Sarcopenia, Cachexia and Wasting Disorders". Sarcopenia, Cachexia and Wasting Disorders. Retrieved 2017-05-17.
  19. ^ Search Results for author Anker SD on PubMed.
  20. ^ Scopus, March 2017, https://www.scopus.com/authid/detail.uri?authorId=56223993400
  21. ^ Evans, William J.; Morley, John E.; Argilés, Josep; Bales, Connie; Baracos, Vickie; Guttridge, Denis; Jatoi, Aminah; Kalantar-Zadeh, Kamyar; Lochs, Herbert (2008-12-01). "Cachexia: a new definition". Clinical Nutrition (Edinburgh, Scotland). 27 (6): 793–799. doi:10.1016/j.clnu.2008.06.013. ISSN 1532-1983. PMID 18718696. S2CID 206821612.
  22. ^ Riegel, Barbara; Moser, Debra K.; Anker, Stefan D.; Appel, Lawrence J.; Dunbar, Sandra B.; Grady, Kathleen L.; Gurvitz, Michelle Z.; Havranek, Edward P.; Lee, Christopher S. (2009-09-22). "State of the science: promoting self-care in persons with heart failure: a scientific statement from the American Heart Association". Circulation. 120 (12): 1141–1163. CiteSeerX 10.1.1.335.9667. doi:10.1161/CIRCULATIONAHA.109.192628. ISSN 1524-4539. PMID 19720935. S2CID 6973440.
  23. ^ Ronco, Claudio; McCullough, Peter; Anker, Stefan D.; Anand, Inder; Aspromonte, Nadia; Bagshaw, Sean M.; Bellomo, Rinaldo; Berl, Tomas; Bobek, Ilona (2017-05-17). "Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative". European Heart Journal. 31 (6): 703–711. doi:10.1093/eurheartj/ehp507. ISSN 0195-668X. PMC 2838681. PMID 20037146.
  24. ^ Argilés, Josep M.; Anker, Stefan D.; Evans, William J.; Morley, John E.; Fearon, Ken C. H.; Strasser, Florian; Muscaritoli, Maurizio; Baracos, Vicky E. (2010-05-01). "Consensus on cachexia definitions". Journal of the American Medical Directors Association. 11 (4): 229–230. doi:10.1016/j.jamda.2010.02.004. ISSN 1538-9375. PMID 20439040.
  25. ^ Morley, John E.; Argiles, Josep M.; Evans, William J.; Bhasin, Shalender; Cella, David; Deutz, Nicolaas E. P.; Doehner, Wolfram; Fearon, Ken C. H.; Ferrucci, Luigi (2017-05-17). "Nutritional Recommendations for the Management of Sarcopenia". Journal of the American Medical Directors Association. 11 (6): 391–396. doi:10.1016/j.jamda.2010.04.014. ISSN 1525-8610. PMC 4623318. PMID 20627179.
  26. ^ Fearon, Kenneth; Strasser, Florian; Anker, Stefan D.; Bosaeus, Ingvar; Bruera, Eduardo; Fainsinger, Robin L.; Jatoi, Aminah; Loprinzi, Charles; MacDonald, Neil (2011-05-01). "Definition and classification of cancer cachexia: an international consensus". The Lancet. Oncology. 12 (5): 489–495. doi:10.1016/S1470-2045(10)70218-7. ISSN 1474-5488. PMID 21296615.
  27. ^ McMurray, John J. V.; Adamopoulos, Stamatis; Anker, Stefan D.; Auricchio, Angelo; Böhm, Michael; Dickstein, Kenneth; Falk, Volkmar; Filippatos, Gerasimos; Fonseca, Cândida (2012-07-01). "ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC". European Heart Journal. 33 (14): 1787–1847. doi:10.1093/eurheartj/ehs104. ISSN 1522-9645. PMID 22611136.
  28. ^ Lip, Gregory Y. H.; Ponikowski, Piotr; Andreotti, Felicita; Anker, Stefan D.; Filippatos, Gerasimos; Homma, Shunichi; Morais, Joao; Pullicino, Patrick; Rasmussen, Lars H. (2012-07-01). "Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis". European Journal of Heart Failure. 14 (7): 681–695. doi:10.1093/eurjhf/hfs073. ISSN 1879-0844. PMID 22611046. S2CID 20956860.
  29. ^ Mancia, Giuseppe; Fagard, Robert; Narkiewicz, Krzysztof; Redon, Josep; Zanchetti, Alberto; Böhm, Michael; Christiaens, Thierry; Cifkova, Renata; De Backer, Guy (2013-07-01). "2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)". European Heart Journal. 34 (28): 2159–2219. doi:10.1093/eurheartj/eht151. hdl:1854/LU-4127523. ISSN 1522-9645. PMID 23771844.
  30. ^ Authors/Task Force Members; Rydén, Lars; Grant, Peter J.; Anker, Stefan D.; Berne, Christian; Cosentino, Francesco; Danchin, Nicolas; Deaton, Christi; Escaned, Javier (2013-10-01). "ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD)". European Heart Journal. 34 (39): 3035–3087. doi:10.1093/eurheartj/eht108. ISSN 1522-9645. PMID 23996285.
  31. ^ Kristensen, Steen Dalby; Knuuti, Juhani; Saraste, Antti; Anker, Stefan; Bøtker, Hans Erik; Hert, Stefan De; Ford, Ian; Gonzalez-Juanatey, Jose Ramón; Gorenek, Bulent (2014-09-14). "2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA)". European Heart Journal. 35 (35): 2383–2431. doi:10.1093/eurheartj/ehu282. ISSN 1522-9645. PMID 25086026.
  32. ^ Anker, Stefan D.; Agewall, Stefan; Borggrefe, Martin; Calvert, Melanie; Jaime Caro, J.; Cowie, Martin R.; Ford, Ian; Paty, Jean A.; Riley, Jillian P. (2014-08-07). "The importance of patient-reported outcomes: a call for their comprehensive integration in cardiovascular clinical trials". European Heart Journal. 35 (30): 2001–2009. doi:10.1093/eurheartj/ehu205. ISSN 1522-9645. PMID 24904027.
  33. ^ Ponikowski, Piotr; Voors, Adriaan A.; Anker, Stefan D.; Bueno, Héctor; Cleland, John G. F.; Coats, Andrew J. S.; Falk, Volkmar; González-Juanatey, José Ramón; Harjola, Veli-Pekka (2016-07-14). "2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC". European Heart Journal. 37 (27): 2129–2200. doi:10.1093/eurheartj/ehw128. ISSN 1522-9645. PMID 27206819.
  34. ^ LLC, Peripheral Brain. "FAIR-HF - Wiki Journal Club". www.wikijournalclub.org. Retrieved 2017-05-17.
  35. ^ Koehler, Friedrich (2010). "Telemedical Interventional Monitoring in Heart Failure (TIM-HF), a randomized, controlled intervention trial investigating the impact of telemedicine on mortality in ambulatory patients with heart failure: study design". European Journal of Heart Failure. 12 (12): 1354–1362. doi:10.1093/eurjhf/hfq199. PMID 21098580. S2CID 32860744.
  36. ^ "Biomarkers in Acute Heart Failure - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. 30 July 2008. Retrieved 2017-05-17.
  37. ^ Anker, Stefan D.; Coats, Andrew J. S.; Cristian, Gabriel; Dragomir, Dinu; Pusineri, Enrico; Piredda, Massimo; Bettari, Luca; Dowling, Robert; Volterrani, Maurizio (2015-09-07). "A prospective comparison of alginate-hydrogel with standard medical therapy to determine impact on functional capacity and clinical outcomes in patients with advanced heart failure (AUGMENT-HF trial)". European Heart Journal. 36 (34): 2297–2309. doi:10.1093/eurheartj/ehv259. ISSN 1522-9645. PMC 4561351. PMID 26082085.
  38. ^ Rosenfield, Kenneth; Matsumura, Jon S.; Chaturvedi, Seemant; Riles, Tom; Ansel, Gary M.; Metzger, D. Chris; Wechsler, Lawrence; Jaff, Michael R.; Gray, William (2016-03-17). "Randomized Trial of Stent versus Surgery for Asymptomatic Carotid Stenosis". New England Journal of Medicine. 374 (11): 1011–1020. doi:10.1056/NEJMoa1515706. ISSN 0028-4793. PMID 26886419.
  39. ^ "A Clinical Evaluation of the Safety and Effectiveness of the MitraClip System in the Treatment of Clinically Significant Functional Mitral Regurgitation - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2017-05-17.
  40. ^ "Impulse Dynamics announced the first enrollment in the IMPULSE-HF European Randomized Efficacy Study - INT". www.impulse-dynamics.com. Retrieved 2017-05-17.
  41. ^ "Clinical Trials Register". www.clinicaltrialsregister.eu. Retrieved 2017-05-17.
  42. ^ a b "Universitätsmedizin Göttingen - Innovative Clinical Trials". www.herzzentrum-goettingen.de. Retrieved 2017-05-17.
  43. ^ "EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved) - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2017-05-17.
  44. ^ "HCR Clarivate Analytics". Retrieved 2017-05-17.
  45. ^ Council on Clinical Cardiology: Scientific Sessions 2006 Highlights (PDF) (Report). November 2006. p. 19. Archived from the original (PDF) on 2016-10-20. [better source needed]
  46. ^ https://www.fnp.org.pl/en/laureaci-nagrody-copernicus-2018/
  47. ^ "Copernicus Award 2018 for Stefan Anker". Retrieved 2018-11-08.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Stefan_D._Anker&oldid=1230687671"